You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
步長製藥(603858.SH)擬向南京華派增資6112.36萬元 進軍疫苗行業
格隆匯 01-16 21:22

格隆匯1月16日丨步長製藥(603858.SH)公佈,為實現步長製藥從銷售型向科研型轉換、從天然藥物(中藥)(植物藥、動物藥、礦物藥)向全醫藥產業鏈轉換、從本土化向全球化轉換的發展規劃,公司擬涉足疫苗領域,基於此,公司向南京華派生物醫藥有限公司(以下簡稱“南京華派”)增資。

公司出資人民幣6112.36萬元對南京華派進行增資,增資完成後,佔南京華派註冊資本的比例為54.4%;根據《山東步長製藥股份有限公司股權投資項目跟隨投資管理辦法》的相關規定,蒲曉平(公司董事、董事會祕書、副總裁)、王寶才(公司財務總監)對本次增資進行跟投,蒲曉平出資人民幣112.36萬元,增資完成後,佔南京華派註冊資本的比例為1%;王寶才出資人民幣11.24萬元,增資完成後,佔南京華派註冊資本的比例為0.1%。本次增資完成後,南京華派的註冊資本將由5000萬元增加至1.12億元。

南京華派擁有成熟且完整的疫苗科研、生產產業鏈,包括作為生產主體的全資子公司浙江天元生物藥業有限公司、作為科研主體的全資子公司泰州賽華生物科技有限公司及無錫華派生物科技有限公司,故步長製藥本次向南京華派的增資可控股浙江天元、泰州賽華、無錫華派,以實現進軍疫苗行業的戰略規劃,進一步增強市場競爭力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account